• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

ImaRx agent completes phase I trials

Article

A new vascular ultrasound contrast agent under development by ImaRx Pharmaceutical has finishedphase I clinical trials, the Tucson company said this month. MRX-115Aerosomes is the first ImaRx agent based on the company's Aerosomestechnology, which ImaRx

A new vascular ultrasound contrast agent under development by ImaRx Pharmaceutical has finishedphase I clinical trials, the Tucson company said this month. MRX-115Aerosomes is the first ImaRx agent based on the company's Aerosomestechnology, which ImaRx claims may be able to significantly enhancegray-scale ultrasound scans in cardiac, blood pool, kidney andliver imaging.

MRX-115 Aerosomes consists of sterile phospholipid-coated microbubbleswith a mean diameter of 2.5 microns. ImaRx plans to use the Aerosomestechnology to develop targeted, site-specific agents for imagingand drug delivery for lymph nodes and diseased tissue.

ImaRx said the phase I trials gave positive results for useof MRX-115 in myocardial perfusion imaging and indicated thatthe agent has a wide safety profile relative to the dose neededfor clinical efficacy. Phase II trials will begin later this year,and ImaRx plans to pursue additional indications for MRX-115 suchas imaging of liver and kidney perfusion.

ImaRx is the developer of SonoRx, an oral ultrasound contrastagent for abdominal imaging under license to Bracco Diagnostics(SCAN 7/27/94 and 3/10/93).

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.